APA (7th ed.) Citation

Pavlinsky, S. L., & Shabalkin, P. I. (2017). THE USE OF PALBOCKLIB, A CYCLINE-DEPENDENT KINASE 4/6 INHIBITOR, IN THE TREATMENT OF METASTATIC BREAST CANCER. A COST-CONSEQUENCE ANALYSIS. Russian Academy of Sciences, Tomsk National Research Medical Center.

Chicago Style (17th ed.) Citation

Pavlinsky, S. L., and P. I. Shabalkin. THE USE OF PALBOCKLIB, A CYCLINE-DEPENDENT KINASE 4/6 INHIBITOR, IN THE TREATMENT OF METASTATIC BREAST CANCER. A COST-CONSEQUENCE ANALYSIS. Russian Academy of Sciences, Tomsk National Research Medical Center, 2017.

MLA (9th ed.) Citation

Pavlinsky, S. L., and P. I. Shabalkin. THE USE OF PALBOCKLIB, A CYCLINE-DEPENDENT KINASE 4/6 INHIBITOR, IN THE TREATMENT OF METASTATIC BREAST CANCER. A COST-CONSEQUENCE ANALYSIS. Russian Academy of Sciences, Tomsk National Research Medical Center, 2017.